The Savara molgramostim FDA decision will not arrive on time: Savara said on Friday, 20 November 2026, that the US Food and Drug Administration told it the agency will not act on the Biologics License Application for inhaled molgramostim (proposed brand name Molbreevi) in autoimmune pulmonary alveolar proteinosis (aPAP) by the 22 November target date, and has given no new date. Shares fell as much as 18% at Friday’s open.
Key takeaways on the Savara molgramostim FDA delay
- The FDA will miss the 22 November 2026 PDUFA date for molgramostim in aPAP; the review is ongoing and no revised action date was provided.
- This is not a rejection. No complete response letter has been issued, and Savara gave no reason for the delay.
- It is the third setback on the path to a decision, after a 2025 refusal to file over manufacturing data and a three-month extension in April 2026.
- Savara stock dropped to about $4.26 at the open from a $5.21 close on Thursday, before recovering part of the loss.
- Analysts at Jefferies and Guggenheim still expect approval and point to possible FDA workload limits.
What Savara disclosed
In a short statement issued before the market opened, Savara said the FDA had informed it that action would not come by the goal date. “The review of the BLA is ongoing and no revised action date has been provided by the agency,” the company said. Savara said it would keep working closely with the agency to finish the review.
What the statement did not say matters as much. There was no mention of a new safety or efficacy question, no request for another trial and no manufacturing inspection finding. A missed PDUFA date with no explanation leaves investors and patients with an open-ended wait rather than a defined new deadline.
A long road to a decision
| When | Event | Effect |
|---|---|---|
| June 2024 | IMPALA-2 Phase 3 meets primary endpoint, a gas-transfer measure of lung function at 24 weeks | Basis for the filing |
| 2025 | FDA refuses to file the first BLA over chemistry, manufacturing and controls (CMC) data | Savara addresses the gaps and refiles |
| 15 April 2026 | FDA classes responses to late-cycle questions as a major amendment | Standard three-month extension, goal date moves to 22 Nov 2026 |
| 20 November 2026 | FDA says it will not act by the goal date | No new date; review continues |
When the FDA extended the review in April, Savara said the agency had not identified safety, efficacy or manufacturing concerns at that point. Molgramostim holds fast track, breakthrough therapy and orphan drug designations in the US.
What molgramostim is meant to treat
Autoimmune PAP is a rare lung disease in which the immune system makes antibodies against GM-CSF, a signalling protein that the lungs’ clean-up cells, alveolar macrophages, need to work. Without it, surfactant, the slippery material that lines the air sacs, builds up and blocks oxygen from moving into the blood. Patients become short of breath and some need whole-lung lavage, a procedure under general anaesthesia in which the lungs are washed out with saline. There is no approved drug for the disease in the US.
Molgramostim is an inhaled form of GM-CSF delivered by nebuliser, designed to replace the signal the antibodies block. In IMPALA-2, the 48-week Phase 3 trial, it significantly improved a measure of how well the lungs transfer gas compared with placebo at 24 weeks, according to Savara and BioSpace reporting.
How Wall Street read the delay
Analysts largely treated the news as a timing problem, not a verdict on the drug. Jefferies said it still had high confidence in approval and noted that the FDA chose to postpone rather than send a complete response letter, which it said may point to bandwidth issues at the agency. It suggested a decision could still allow a US launch in early 2027 and estimated peak sales of more than $500 million if approved. Jefferies also flagged that manufacturing could again be a factor, given the history. Guggenheim said it has long believed the clinical data are sufficient for approval and that the company has taken the right steps on manufacturing.
The market was less calm. Savara shares opened about 18% lower at $4.26 and traded near $4.50 later in the morning, roughly 14% below Thursday’s close, by our calculation from reported prices.
Market context: inhaled medicines
If approved, molgramostim would join a large class of medicines given by inhalation. Acumen Research and Consulting projected the global inhalable drugs market would grow at about 6.4% a year from 2019 to reach around US$41.5 billion in 2026, with respiratory disease the largest application and North America the largest region. That report was last updated in January 2020, so its figures are dated and best read as indicative. A rare-disease biologic like molgramostim would be a small, specialised slice of that market, but one where the lack of any approved alternative gives it pricing power.
What to watch next
- Any FDA communication setting a new action date, or a complete response letter that would spell out remaining issues.
- Whether Savara discloses a pending manufacturing inspection or further information requests.
- Other 22 November decisions, including Capricor’s deramiocel in Duchenne muscular dystrophy, which we previewed in our Capricor report, as a read on whether delays are spreading.
- Savara’s cash position and financing plans if the wait stretches into 2027.
FAQ
Did the FDA reject Savara’s molgramostim?
No. The FDA has not issued a complete response letter. It simply will not act by the 22 November 2026 target date, and the review continues.
When will the FDA decide on Molbreevi?
Unknown. Savara said the agency gave no revised action date. Analysts at Jefferies think a decision could still allow a launch in early 2027.
What is autoimmune pulmonary alveolar proteinosis?
A rare lung disease in which antibodies against GM-CSF stop lung immune cells from clearing surfactant, which builds up in the air sacs and makes breathing difficult. There is no FDA-approved drug for it.
Sources: Savara press release (20 Nov 2026); BioSpace; RTTNews; BioPharm International. Market data: Acumen Research and Consulting. Not medical or investment advice. Last updated 21 November 2026. More in Pharmaceuticals.



